APO Research
Talk to an analyst

APO RESEARCH · REPORT

Intraveno (IV) Iron Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Intraveno (IV) Iron Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025195 pages

Choose your research edition.

Industry ResearchIntraveno (IV) Iron Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Intraveno (IV) Iron Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Intraveno (IV) Iron Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Intraveno (IV) Iron Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Intraveno (IV) Iron Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Intraveno (IV) Iron Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Intraveno (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Intraveno (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Intraveno (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Intraveno (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Intraveno (IV) Iron Drugs include Sanofi, Vifor Pharma, Pharmacosmos, Luitpold Pharmaceuticals, Galenica, Fresenius Medical Care, American Regent, AMAG Pharmaceuticals and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Intraveno (IV) Iron Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Intraveno (IV) Iron Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Intraveno (IV) Iron Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Intraveno (IV) Iron Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Intraveno (IV) Iron Drugs Segment by Company

Sanofi

Vifor Pharma

Pharmacosmos

Luitpold Pharmaceuticals

Galenica

Fresenius Medical Care

American Regent

AMAG Pharmaceuticals

Allergan

Actavis

Intraveno (IV) Iron Drugs Segment by Type

Low Molecular Weight Iron Dextran

Ferric Gluconate

Ferric Carboxyl Maltose

Iron Sucrose

Intraveno (IV) Iron Drugs Segment by Application

Ambulatory Surgical Centers

Hospitals

Diagnostic Centers

Intraveno (IV) Iron Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intraveno (IV) Iron Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Intraveno (IV) Iron Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intraveno (IV) Iron Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Intraveno (IV) Iron Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Intraveno (IV) Iron Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Intraveno (IV) Iron Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Intraveno (IV) Iron Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Intraveno (IV) Iron Drugs Industry Trends Table 2. Intraveno (IV) Iron Drugs Industry Drivers Table 3. Intraveno (IV) Iron Drugs Industry Opportunities and Challenges Table 4. Intraveno (IV) Iron Drugs Industry Restraints Table 5. Global Intraveno (IV) Iron Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Intraveno (IV) Iron Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Intraveno (IV) Iron Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Intraveno (IV) Iron Drugs Sales Market Share by Manufacturers Table 9. Global Intraveno (IV) Iron Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Intraveno (IV) Iron Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Intraveno (IV) Iron Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Intraveno (IV) Iron Drugs Manufacturers, Product Type & Application Table 13. Global Intraveno (IV) Iron Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Intraveno (IV) Iron Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Low Molecular Weight Iron Dextran Table 17. Major Manufacturers of Ferric Gluconate Table 18. Major Manufacturers of Ferric Carboxyl Maltose Table 19. Major Manufacturers of Iron Sucrose Table 20. Global Intraveno (IV) Iron Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Intraveno (IV) Iron Drugs Sales by Type (2021-2026) & (K Units) Table 22. Global Intraveno (IV) Iron Drugs Sales by Type (2027-2032) & (K Units) Table 23. Global Intraveno (IV) Iron Drugs Sales Market Share by Type (2021-2026) Table 24. Global Intraveno (IV) Iron Drugs Sales Market Share by Type (2027-2032) Table 25. Global Intraveno (IV) Iron Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Intraveno (IV) Iron Drugs Revenue by Type (2021-2026) & (K Units) Table 27. Global Intraveno (IV) Iron Drugs Revenue by Type (2027-2032) & (K Units) Table 28. Global Intraveno (IV) Iron Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Intraveno (IV) Iron Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Ambulatory Surgical Centers Table 31. Major Manufacturers of Hospitals Table 32. Major Manufacturers of Diagnostic Centers Table 33. Global Intraveno (IV) Iron Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Intraveno (IV) Iron Drugs Sales by Application (2021-2026) & (K Units) Table 35. Global Intraveno (IV) Iron Drugs Sales by Application (2027-2032) & (K Units) Table 36. Global Intraveno (IV) Iron Drugs Sales Market Share by Application (2021-2026) Table 37. Global Intraveno (IV) Iron Drugs Sales Market Share by Application (2027-2032) Table 38. Global Intraveno (IV) Iron Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Intraveno (IV) Iron Drugs Revenue by Application (2021-2026) & (K Units) Table 40. Global Intraveno (IV) Iron Drugs Revenue by Application (2027-2032) & (K Units) Table 41. Global Intraveno (IV) Iron Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Intraveno (IV) Iron Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Intraveno (IV) Iron Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Intraveno (IV) Iron Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Intraveno (IV) Iron Drugs Sales Market Share by Region (2021-2026) Table 46. Global Intraveno (IV) Iron Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Intraveno (IV) Iron Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Intraveno (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Intraveno (IV) Iron Drugs Sales by Country (2021-2026) & (K Units) Table 50. North America Intraveno (IV) Iron Drugs Sales by Country (2027-2032) & (K Units) Table 51. Europe Intraveno (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Intraveno (IV) Iron Drugs Sales by Country (2021-2026) & (K Units) Table 53. Europe Intraveno (IV) Iron Drugs Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Intraveno (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Intraveno (IV) Iron Drugs Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Intraveno (IV) Iron Drugs Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Intraveno (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Intraveno (IV) Iron Drugs Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Intraveno (IV) Iron Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Intraveno (IV) Iron Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Intraveno (IV) Iron Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Intraveno (IV) Iron Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Intraveno (IV) Iron Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Intraveno (IV) Iron Drugs Revenue Market Share by Region (2027-2032) Table 65. Sanofi Company Information Table 66. Sanofi Business Overview Table 67. Sanofi Intraveno (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sanofi Intraveno (IV) Iron Drugs Product Portfolio Table 69. Sanofi Recent Development Table 70. Vifor Pharma Company Information Table 71. Vifor Pharma Business Overview Table 72. Vifor Pharma Intraveno (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Vifor Pharma Intraveno (IV) Iron Drugs Product Portfolio Table 74. Vifor Pharma Recent Development Table 75. Pharmacosmos Company Information Table 76. Pharmacosmos Business Overview Table 77. Pharmacosmos Intraveno (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Pharmacosmos Intraveno (IV) Iron Drugs Product Portfolio Table 79. Pharmacosmos Recent Development Table 80. Luitpold Pharmaceuticals Company Information Table 81. Luitpold Pharmaceuticals Business Overview Table 82. Luitpold Pharmaceuticals Intraveno (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Luitpold Pharmaceuticals Intraveno (IV) Iron Drugs Product Portfolio Table 84. Luitpold Pharmaceuticals Recent Development Table 85. Galenica Company Information Table 86. Galenica Business Overview Table 87. Galenica Intraveno (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Galenica Intraveno (IV) Iron Drugs Product Portfolio Table 89. Galenica Recent Development Table 90. Fresenius Medical Care Company Information Table 91. Fresenius Medical Care Business Overview Table 92. Fresenius Medical Care Intraveno (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Fresenius Medical Care Intraveno (IV) Iron Drugs Product Portfolio Table 94. Fresenius Medical Care Recent Development Table 95. American Regent Company Information Table 96. American Regent Business Overview Table 97. American Regent Intraveno (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. American Regent Intraveno (IV) Iron Drugs Product Portfolio Table 99. American Regent Recent Development Table 100. AMAG Pharmaceuticals Company Information Table 101. AMAG Pharmaceuticals Business Overview Table 102. AMAG Pharmaceuticals Intraveno (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. AMAG Pharmaceuticals Intraveno (IV) Iron Drugs Product Portfolio Table 104. AMAG Pharmaceuticals Recent Development Table 105. Allergan Company Information Table 106. Allergan Business Overview Table 107. Allergan Intraveno (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Allergan Intraveno (IV) Iron Drugs Product Portfolio Table 109. Allergan Recent Development Table 110. Actavis Company Information Table 111. Actavis Business Overview Table 112. Actavis Intraveno (IV) Iron Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Actavis Intraveno (IV) Iron Drugs Product Portfolio Table 114. Actavis Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Intraveno (IV) Iron Drugs Distributors List Table 118. Intraveno (IV) Iron Drugs Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Intraveno (IV) Iron Drugs Product Image Figure 2. Global Intraveno (IV) Iron Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Intraveno (IV) Iron Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Intraveno (IV) Iron Drugs Sales (2021-2032) & (K Units) Figure 5. Global Intraveno (IV) Iron Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Intraveno (IV) Iron Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Low Molecular Weight Iron Dextran Image Figure 9. Ferric Gluconate Image Figure 10. Ferric Carboxyl Maltose Image Figure 11. Iron Sucrose Image Figure 12. Global Intraveno (IV) Iron Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Intraveno (IV) Iron Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Intraveno (IV) Iron Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Intraveno (IV) Iron Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Intraveno (IV) Iron Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Intraveno (IV) Iron Drugs Revenue Market Share by Type (2021-2032) Figure 18. Ambulatory Surgical Centers Image Figure 19. Hospitals Image Figure 20. Diagnostic Centers Image Figure 21. Global Intraveno (IV) Iron Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Intraveno (IV) Iron Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Intraveno (IV) Iron Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Intraveno (IV) Iron Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Intraveno (IV) Iron Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Intraveno (IV) Iron Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Intraveno (IV) Iron Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Intraveno (IV) Iron Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Intraveno (IV) Iron Drugs Sales Market Share by Country (2021-2032) Figure 41. China Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Intraveno (IV) Iron Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Intraveno (IV) Iron Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Intraveno (IV) Iron Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Intraveno (IV) Iron Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Intraveno (IV) Iron Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Intraveno (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Intraveno (IV) Iron Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Intraveno (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Intraveno (IV) Iron Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Intraveno (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Intraveno (IV) Iron Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Intraveno (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Intraveno (IV) Iron Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Intraveno (IV) Iron Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Low Molecular Weight Iron Dextran
  • Ferric Gluconate
  • Ferric Carboxyl Maltose
  • Iron Sucrose
Applications
  • Ambulatory Surgical Centers
  • Hospitals
  • Diagnostic Centers
Companies covered
  • Sanofi
  • Vifor Pharma
  • Pharmacosmos
  • Luitpold Pharmaceuticals
  • Galenica
  • Fresenius Medical Care
  • American Regent
  • AMAG Pharmaceuticals
  • Allergan
  • Actavis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Intraveno (IV) Iron Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Intraveno (IV) Iron Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Intraveno (IV) Iron Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Intraveno (IV) Iron Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Intraveno (IV) Iron Drugs Market Dynamics
  1. 2.1 Intraveno (IV) Iron Drugs Industry Trends
  2. 2.2 Intraveno (IV) Iron Drugs Industry Drivers
  3. 2.3 Intraveno (IV) Iron Drugs Industry Opportunities and Challenges
  4. 2.4 Intraveno (IV) Iron Drugs Industry Restraints
3 Intraveno (IV) Iron Drugs Market by Manufacturers
  1. 3.1 Global Intraveno (IV) Iron Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Intraveno (IV) Iron Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Intraveno (IV) Iron Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Intraveno (IV) Iron Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Intraveno (IV) Iron Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Intraveno (IV) Iron Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Intraveno (IV) Iron Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Intraveno (IV) Iron Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Intraveno (IV) Iron Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Intraveno (IV) Iron Drugs Tier 1, Tier 2, and Tier 3
4 Intraveno (IV) Iron Drugs Market by Type
  1. 4.1 Intraveno (IV) Iron Drugs Type Introduction
  2. 4.1.1 Low Molecular Weight Iron Dextran
  3. 4.1.2 Ferric Gluconate
  4. 4.1.3 Ferric Carboxyl Maltose
  5. 4.1.4 Iron Sucrose
  6. 4.2 Global Intraveno (IV) Iron Drugs Sales by Type
  7. 4.2.1 Global Intraveno (IV) Iron Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Intraveno (IV) Iron Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Intraveno (IV) Iron Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Intraveno (IV) Iron Drugs Revenue by Type
  11. 4.3.1 Global Intraveno (IV) Iron Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Intraveno (IV) Iron Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Intraveno (IV) Iron Drugs Revenue Market Share by Type (2021-2032)
5 Intraveno (IV) Iron Drugs Market by Application
  1. 5.1 Intraveno (IV) Iron Drugs Application Introduction
  2. 5.1.1 Ambulatory Surgical Centers
  3. 5.1.2 Hospitals
  4. 5.1.3 Diagnostic Centers
  5. 5.2 Global Intraveno (IV) Iron Drugs Sales by Application
  6. 5.2.1 Global Intraveno (IV) Iron Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Intraveno (IV) Iron Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Intraveno (IV) Iron Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Intraveno (IV) Iron Drugs Revenue by Application
  10. 5.3.1 Global Intraveno (IV) Iron Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Intraveno (IV) Iron Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Intraveno (IV) Iron Drugs Revenue Market Share by Application (2021-2032)
6 Global Intraveno (IV) Iron Drugs Sales by Region
  1. 6.1 Global Intraveno (IV) Iron Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Intraveno (IV) Iron Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Intraveno (IV) Iron Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Intraveno (IV) Iron Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Intraveno (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Intraveno (IV) Iron Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Intraveno (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Intraveno (IV) Iron Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Intraveno (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Intraveno (IV) Iron Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Intraveno (IV) Iron Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Intraveno (IV) Iron Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Intraveno (IV) Iron Drugs Revenue by Region
  1. 7.1 Global Intraveno (IV) Iron Drugs Revenue by Region
  2. 7.1.1 Global Intraveno (IV) Iron Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Intraveno (IV) Iron Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Intraveno (IV) Iron Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Intraveno (IV) Iron Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Intraveno (IV) Iron Drugs Revenue (2021-2032)
  8. 7.2.2 North America Intraveno (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Intraveno (IV) Iron Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Intraveno (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Intraveno (IV) Iron Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Intraveno (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Intraveno (IV) Iron Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Intraveno (IV) Iron Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Intraveno (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Intraveno (IV) Iron Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Vifor Pharma
  8. 8.2.1 Vifor Pharma Company Information
  9. 8.2.2 Vifor Pharma Business Overview
  10. 8.2.3 Vifor Pharma Intraveno (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Vifor Pharma Intraveno (IV) Iron Drugs Product Portfolio
  12. 8.2.5 Vifor Pharma Recent Developments
  13. 8.3 Pharmacosmos
  14. 8.3.1 Pharmacosmos Company Information
  15. 8.3.2 Pharmacosmos Business Overview
  16. 8.3.3 Pharmacosmos Intraveno (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pharmacosmos Intraveno (IV) Iron Drugs Product Portfolio
  18. 8.3.5 Pharmacosmos Recent Developments
  19. 8.4 Luitpold Pharmaceuticals
  20. 8.4.1 Luitpold Pharmaceuticals Company Information
  21. 8.4.2 Luitpold Pharmaceuticals Business Overview
  22. 8.4.3 Luitpold Pharmaceuticals Intraveno (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Luitpold Pharmaceuticals Intraveno (IV) Iron Drugs Product Portfolio
  24. 8.4.5 Luitpold Pharmaceuticals Recent Developments
  25. 8.5 Galenica
  26. 8.5.1 Galenica Company Information
  27. 8.5.2 Galenica Business Overview
  28. 8.5.3 Galenica Intraveno (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Galenica Intraveno (IV) Iron Drugs Product Portfolio
  30. 8.5.5 Galenica Recent Developments
  31. 8.6 Fresenius Medical Care
  32. 8.6.1 Fresenius Medical Care Company Information
  33. 8.6.2 Fresenius Medical Care Business Overview
  34. 8.6.3 Fresenius Medical Care Intraveno (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fresenius Medical Care Intraveno (IV) Iron Drugs Product Portfolio
  36. 8.6.5 Fresenius Medical Care Recent Developments
  37. 8.7 American Regent
  38. 8.7.1 American Regent Company Information
  39. 8.7.2 American Regent Business Overview
  40. 8.7.3 American Regent Intraveno (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 American Regent Intraveno (IV) Iron Drugs Product Portfolio
  42. 8.7.5 American Regent Recent Developments
  43. 8.8 AMAG Pharmaceuticals
  44. 8.8.1 AMAG Pharmaceuticals Company Information
  45. 8.8.2 AMAG Pharmaceuticals Business Overview
  46. 8.8.3 AMAG Pharmaceuticals Intraveno (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AMAG Pharmaceuticals Intraveno (IV) Iron Drugs Product Portfolio
  48. 8.8.5 AMAG Pharmaceuticals Recent Developments
  49. 8.9 Allergan
  50. 8.9.1 Allergan Company Information
  51. 8.9.2 Allergan Business Overview
  52. 8.9.3 Allergan Intraveno (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Allergan Intraveno (IV) Iron Drugs Product Portfolio
  54. 8.9.5 Allergan Recent Developments
  55. 8.10 Actavis
  56. 8.10.1 Actavis Company Information
  57. 8.10.2 Actavis Business Overview
  58. 8.10.3 Actavis Intraveno (IV) Iron Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Actavis Intraveno (IV) Iron Drugs Product Portfolio
  60. 8.10.5 Actavis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Intraveno (IV) Iron Drugs Value Chain Analysis
  2. 9.1.1 Intraveno (IV) Iron Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Intraveno (IV) Iron Drugs Production Mode & Process
  6. 9.2 Intraveno (IV) Iron Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Intraveno (IV) Iron Drugs Distributors
  9. 9.2.3 Intraveno (IV) Iron Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst